Cognitive decline in the elderly: a double-blind, placebo-controlled multicenter study on efficacy of phosphatidylserine administration.
This double-blind study assesses the therapeutic efficacy and the safety of oral treatment with phosphatidylserine (BC-PS) vs placebo (300 mg/day for 6 months) in a group of geriatric patients with cognitive impairment. A total of 494 elderly patients (age between 65 and 93 years), with moderate to severe cognitive decline, according to the Mini Mental State Examination and Global Deterioration Scale, were recruited in 23 Geriatric or General Medicine Units in Northeastern Italy. Sixty-nine patients dropped out within the 6-month trial period. Patients were examined just before starting therapy, and 3 and 6 months thereafter. The efficacy of treatment compared to placebo was measured on the basis of changes occurring in behavior and cognitive performance using the Plutchik Geriatric Rating Scale and the Buschke Selective Reminding Test. Statistically significant improvements in the phosphatidylserine-treated group compared to placebo were observed both in terms of behavioral and cognitive parameters. In addition, clinical evaluation and laboratory tests demonstrated that BC-PS was well tolerated. These results are clinically important since the patients were representative of the geriatric population commonly met in clinical practice.
Cenacchi
T
T
Fidia Research Laboratories, Abano Terme (Padova), Italy.
Bertoldin
T
T
Farina
C
C
Fiori
M G
MG
Crepaldi
G
G
D000203:Activities of Daily Living; D000368:Aged; D000369:Aged, 80 and over; D003072:Cognition Disorders / Q000517:prevention & control*; D004311:Double-Blind Method; D005260:Female; D016330:Frail Elderly; D006801:Humans; D008297:Male; D008606:Mental Processes / Q000187:drug effects; D008609:Mental Status Schedule; D010352:Patient Dropouts; D010718:Phosphatidylserines / Q000494:pharmacology / Q000627:therapeutic use*; D011569:Psychiatric Status Rating Scales
D010718:Phosphatidylserines